Published in

Ferrata Storti Foundation, Haematologica, 4(93), p. 560-565

DOI: 10.3324/haematol.12106

Links

Tools

Export citation

Search in Google Scholar

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Journal article published in 2008 by M.-V. (María Victoria) Mateos, José M. (J M.) Hernandez, Miguel T. (M T.) Hernandez, Norma C. (N C.) Gutierrez, L. (Luis) Palomera, M. (M.) Fuertes, P. (P.) Garcia-Sanchez, Juán J. (Juan J.) Lahuerta, Javier de la Rubia ORCID, J. (J.) de la Rubia, M.-J. (María José) Terol, A. (Anna) Sureda, J. (J.) Bargay, P. (Paz) Ribas, A. (A.) Alegre and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone with novel agents. We previously reported an 89% response rate, including 32% complete responses and 11% near complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP) in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome.